MerckMRK
About: Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Employees: 75,000
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
11% more call options, than puts
Call options by funds: $2.57B | Put options by funds: $2.32B
1.09% less ownership
Funds ownership: 77.91% [Q4 2024] → 76.82% (-1.09%) [Q1 2025]
5% less funds holding
Funds holding: 3,550 [Q4 2024] → 3,380 (-170) [Q1 2025]
10% less funds holding in top 10
Funds holding in top 10: 71 [Q4 2024] → 64 (-7) [Q1 2025]
10% less capital invested
Capital invested by funds: $196B [Q4 2024] → $177B (-$19.4B) [Q1 2025]
16% less repeat investments, than reductions
Existing positions increased: 1,319 | Existing positions reduced: 1,572
35% less first-time investments, than exits
New positions opened: 179 | Existing positions closed: 275
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Wells Fargo Mohit Bansal | 14%upside $90 | Equal-Weight Maintained | 30 Jul 2025 |
Morgan Stanley Terence Flynn | 24%upside $98 | Equal-Weight Maintained | 10 Jul 2025 |
Citigroup Andrew Baum | 6%upside $84 | Neutral Downgraded | 14 May 2025 |
Financial journalist opinion
Based on 99 articles about MRK published over the past 30 days
